These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 21947887)

  • 41. Arterial hypertension and proteinuria in pediatric chronic kidney disease.
    Simonetti GD; Bucher BS; Tschumi S; Lava SA; Bianchetti MG
    Minerva Pediatr; 2012 Apr; 64(2):171-82. PubMed ID: 22495191
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emerging drugs which target the renin-angiotensin-aldosterone system.
    Steckelings UM; Paulis L; Unger T; Bader M
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):619-30. PubMed ID: 21905943
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of dual inhibition of renin-angiotensin-aldosterone system on cardiovascular and renal outcomes: balancing the risks and the benefits.
    Tocci G; Citoni B; Presta V; Leoncini G; Viazzi F; Bonino B; Volpe M; Pontremoli R
    Intern Emerg Med; 2020 Apr; 15(3):373-379. PubMed ID: 31865522
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
    Krum H; Gilbert RE
    J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The blockade of renin-angiotensin-aldosterone system in hemodialysis patients to control hypertension and prevent cardiovascular disease: optimal pharmacotherapy.
    Morishita Y; Kusano E
    Cardiovasc Hematol Agents Med Chem; 2011 Oct; 9(4):241-6. PubMed ID: 22023537
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level.
    Bokuda K; Morimoto S; Seki Y; Yatabe M; Watanabe D; Yatabe J; Ando T; Shimizu S; Itoh H; Ichihara A
    Hypertens Res; 2018 Jun; 41(6):435-443. PubMed ID: 29618841
    [TBL] [Abstract][Full Text] [Related]  

  • 48. John Laragh and the renin thesis: creating a paradigm.
    Weber MA
    Am J Hypertens; 2014 Aug; 27(8):1008-9. PubMed ID: 25103931
    [No Abstract]   [Full Text] [Related]  

  • 49. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Activated intrarenal renin-angiotensin system is correlated with high blood pressure in humans.
    Kobori H; Fu Q; Crowley SD; Gonzalez-Villalobos RA; Campos RR
    J Appl Physiol (1985); 2010 Dec; 109(6):2003. PubMed ID: 21148352
    [No Abstract]   [Full Text] [Related]  

  • 50. Genetic associations between genes in the renin-angiotensin-aldosterone system and renal disease: a systematic review and meta-analysis.
    Smyth LJ; Cañadas-Garre M; Cappa RC; Maxwell AP; McKnight AJ
    BMJ Open; 2019 May; 9(4):e026777. PubMed ID: 31048445
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Counterpoint: Activation of the intrarenal renin-angiotensin system is the dominant contributor to systemic hypertension.
    Navar LG
    J Appl Physiol (1985); 2010 Dec; 109(6):1998-2000; discussion 2015. PubMed ID: 21148349
    [No Abstract]   [Full Text] [Related]  

  • 52. Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.
    Ku E; McCulloch CE; Vittinghoff E; Lin F; Johansen KL
    J Am Heart Assoc; 2018 Oct; 7(19):e009992. PubMed ID: 30371331
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Revisiting RAAS blockade in CKD with newer potassium-binding drugs.
    Georgianos PI; Agarwal R
    Kidney Int; 2018 Feb; 93(2):325-334. PubMed ID: 29276100
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Blood Pressure Lowering and Safety Improvements With Liver Angiotensinogen Inhibition in Models of Hypertension and Kidney Injury.
    Mullick AE; Yeh ST; Graham MJ; Engelhardt JA; Prakash TP; Crooke RM
    Hypertension; 2017 Sep; 70(3):566-576. PubMed ID: 28716988
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. AT1 receptors in the kidney mediate the chronic hypertensive response to angiotensin II.
    Crowley SD
    J Appl Physiol (1985); 2010 Dec; 109(6):2012-3. PubMed ID: 21188828
    [No Abstract]   [Full Text] [Related]  

  • 56. Targeting the Renin-Angiotensin-Aldosterone System to Prevent Hypertension and Kidney Disease of Developmental Origins.
    Hsu CN; Tain YL
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669059
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney.
    van den Heuvel M; Batenburg WW; Jainandunsing S; Garrelds IM; van Gool JM; Feelders RA; van den Meiracker AH; Danser AH
    J Hypertens; 2011 Nov; 29(11):2147-55. PubMed ID: 21941204
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Flounder Fish Peptide Shows Anti-Hypertensive Effects by Suppressing the Renin-Angiotensin-Aldosterone System and Endothelin-1.
    Rahmdel M; Cho SM; Jeon YJ; Lee DH
    Protein Pept Lett; 2021; 28(7):831-840. PubMed ID: 33573539
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
    Lambers Heerspink HJ; Perkovic V; de Zeeuw D
    J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chronotherapy with a Renin-angiotensin System Inhibitor Ameliorates Renal Damage by Suppressing Intrarenal Renin-angiotensin System Activation.
    Aoki T; Ohashi N; Isobe S; Ishigaki S; Matsuyama T; Sato T; Fujikura T; Kato A; Miyajima H; Yasuda H
    Intern Med; 2020; 59(18):2237-2244. PubMed ID: 32938851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.